PBAC's latest decision on Pioglitazone: Recommended (2025). Considered for Treatment of type 2 diabetes mellitus (T2DM). The submission requested listing of new 30-pack sizes of pioglitazone tablets (15 mg, 30 mg, and 45 mg strengths) as a replacement for the currently PBS-listed 28-pack due to supply shortages.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2025
Submissions
1
2025 → 2025
Eligible population
Adults with type 2 diabetes mellitus requiring treatment with pioglitazone monotherapy, dual therapy (with sulfonylureas, insulin, or metformin), or triple therapy (with sulfonylurea and metformin).
Therapy area
Endocrinology
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
currently PBS-listed 28-tablet packs of Actos (pioglitazone 15 mg, 30 mg, and 45 mg)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis based on equivalent price per tablet; no ICER calculated by design.